This is an old revision of this page, as edited by PrimeBOT(talk | contribs) at 01:25, 25 March 2017(→top: convert deprecated magic links to template usage, update CS1 params in templates - BRFA). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 01:25, 25 March 2017 by PrimeBOT(talk | contribs)(→top: convert deprecated magic links to template usage, update CS1 params in templates - BRFA)
BAY 59-3074 is a drug which is a cannabinoid receptorpartial agonist developed by Bayer AG. It has analgesic effects and is used in scientific research. It is orally active in animals, and has modest affinity for both CB1 and CB2 receptors, with Ki values of 48.3nM at CB1 and 45.5nM at CB2.[1][2]
References
^De Vry J, Denzer D, Reissmueller E, Eijckenboom M, Heil M, Meier H, Mauler F. 3-[2-cyano-3-(trifluoromethyl)phenoxy]phenyl-4,4,4-trifluoro-1-butanesulfonate (BAY 59-3074): a novel cannabinoid Cb1/Cb2 receptor partial agonist with antihyperalgesic and antiallodynic effects. Journal of Pharmacology and Experimental Therapeutics. 2004 Aug;310(2):620-32. PMID15140913
^De Vry J, Jentzsch KR. Discriminative stimulus effects of the structurally novel cannabinoid CB1/CB2 receptor partial agonist BAY 59-3074 in the rat. European Journal of Pharmacology. 2004 Nov 28;505(1-3):127-33. PMID15556145